Registry of biomedical companies:
[3] [A] [B] [C] [D] [E] [F] [G] [H] [I] [J] [K] [L] [M] [N] [O] [P] [Q] [R] [S] [T] [U] [V] [W] [X] [Y] [Z] 460 active entries
440 Burroughs, TechOne Suite 501
Detroit, 48202
United States of America, Michigan
Toll free: 1-866-3TISSUE
Phone: 1-313-263-0960 Fax: 1-313-263-0961
E-Mail:
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
Stock symbol: ATD
Please notice: This entry hasn't been updated by the submitting company for more than 2 years. It could be possible that this company doesn't longer exists.
Description:
Asterand Bioscience, a BioIVT company, is the leading global supplier of high quality, well characterized human tissue and human tissue-based research services to support those engaged in drug discovery & development. Our mission is to accelerate target discovery and compound validation and enable pharmaceutical and biotechnology companies to take safer and more effective drugs into the clinic. Pharmaceutical research is at a critical crossroads. Despite a dramatic increase in R&D budgets, the number of new drug applications is falling because the failure rate in clinical trials remains high. Researchers have always known that animal models provide only a partial guide to drug response in humans. Thus, scientists are becoming increasingly reliant upon human tissue-based models to bridge this knowledge gap and improve decision making during the development of medicines for man. Asterand Bio is the leading company with extensive experience as a human tissue supplier and as a provider of human tissue-based drug discovery services. Formed in January 2006 from the merger of Asterand, a human tissue biorepository, and Pharmagene, a human tissue-based drug discovery company, we are uniquely positioned to provide a comprehensive approach to meet the research needs of pharmaceutical and biotechnology scientists from target identification through to compound evaluation and drug safety. Asterand Bio offers unparalleled access to human tissue through worldwide network of 36 active donor institutions, each of which we collaborate with very closely. Our XpressBANK™ biobank contains several hundred thousand specimens from the broadest range of therapeutic areas and with the most diverse ethnic representation. Our tissues provide high value to our clients; the quantity of material provided for each sample allows scientists to conduct multiple experiments using a single specimen. In addition, our renowned quality assurance procedures provide stringent controls on specimen collection and characterization and on the corresponding clinical data. As part of this process, we also independently confirm pathology and assess RNA integrity of our tissues. Our quality control results are provided to researchers before they purchase so they can choose samples that will best meet their scientific requirements. Through our ProCURE™ service, human tissues and clinical data can also be custom collected to meet special requirements. This includes the collection of follow-up data related to patient outcome. As a result of its history in drug discovery, Asterand Bio’s Services division offers exemplary scientific expertise in human tissue research and we have more than 10 years experience in providing top multinational pharmaceutical companies with human tissue-based services. Through our PhaseZERO® drug discovery services platform, we provide a collaborative scientific approach to deliver human tissue-based data on target & biomarker validation as well as compound potency, efficacy, disposition and safety. Our studies can be custom designed and are conducted on a fee-for-service basis where our clients own and retain all resulting IP and data. Through this combination of an extensive tissue supply network and a proven track record in delivering research services, Asterand is uniquely positioned to provide a complete solution for human tissue research needs. For further information, please e-mail mailto:customerservice@asterand.com or visit us at www.asterandbio.com
Selected Categories:
Last update of this entry: September 26, 2017
|